Ocugen (OCGN) director Uday Kompella awarded 170,100 stock options at $1.22 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ocugen, Inc. director Uday Kompella received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.

The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided he continues serving through the vesting date. Following this grant, Kompella holds 170,100 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kompella Uday

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	170,100	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 170,100 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 170,100 options Exercise price: $1.22/share Expiration date: June 11, 2036 +3 more

6 metrics

Option grant size 170,100 options Stock Option (Right to Buy) granted to director

Exercise price $1.22/share Conversion or exercise price of the options

Expiration date June 11, 2036 Option term end for granted award

Vesting date trigger June 11, 2027 or next annual meeting Earlier date determines vesting, subject to continued service

Options held after grant 170,100 options Total derivative securities following transaction, direct ownership

Transaction price per option $0.00 Grant/award acquisition, no purchase price paid

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vests, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.2200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-11T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests financial

"The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting"

annual meeting of stockholders financial

"Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kompella Uday

(Last)

(First)

(Middle)

C/O OCUGEN, INC.

11 GREAT VALLEY PARKWAY

(Street)

MALVERN

PENNSYLVANIA

19355

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ocugen, Inc. [ OCGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.22	06/11/2026		A		170,100		⁽¹⁾	06/11/2036	Common Stock	170,100	$0	170,100	D

Explanation of Responses:

1. The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Shankar Musunuri, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Ocugen (OCGN) director Uday Kompella report on this Form 4?

Uday Kompella reported receiving a grant of stock options for 170,100 shares of Ocugen common stock. These options are a compensation-related award, not an open-market stock purchase or sale, and are held directly under his name according to the filing.

What is the exercise price of the Ocugen (OCGN) options granted to Uday Kompella?

The granted options have an exercise price of $1.22 per share. This means Kompella can buy Ocugen common stock at $1.22 per share once vested and exercisable, regardless of the market price at that time, subject to the award terms.

When do Uday Kompella’s Ocugen (OCGN) stock options vest?

The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders. Vesting is conditioned on Kompella’s continued service with the company through whichever vesting date occurs first, as disclosed in the footnote.

When do the Ocugen (OCGN) stock options granted to Uday Kompella expire?

The options expire on June 11, 2036. After this expiration date, any unexercised portion of the 170,100 stock options can no longer be used to purchase Ocugen common shares at the $1.22 exercise price specified in the award.

Is this Ocugen (OCGN) Form 4 a buy or sell of common stock?

This Form 4 reports a grant of stock options, categorized as an acquisition, not a market buy or sell of common shares. Kompella received 170,100 options as a compensation award, with no open-market trading reported in this particular filing.

How many Ocugen (OCGN) options does Uday Kompella hold after this transaction?

After the reported grant, Kompella holds 170,100 stock options directly. The filing shows this as his total derivative holdings following the transaction, all tied to options exercisable into Ocugen common stock at an exercise price of $1.22 per share.